Table 1.
Patient characteristics.
| miRNA inception cohort | miRNA validation cohort | cAMP cohort | ||||
|---|---|---|---|---|---|---|
| Patients in remission | Healthy controls | Patients in remission | Healthy controls | Patients in remission | Healthy controls | |
| Basic characteristics | ||||||
| Number (n) | 8 | 8 | 23 | 23 | 10 | 10 |
| Median age (years) | 55.7 (49.6–62.5) | 53.9 (46.0–58.5) | 53.1 (46.0–62.5) | 54.0 (46.3–64.5) | 57.5 (56.0–64.5) | 58.6 (53.1–63.3) |
| Male, n (%) | 5 (62.5%) | 5 (62.5%) | 11 (47.8%) | 13 (56.5%) | 4 (40%) | 4 (40%) |
| Disease Characteristics | ||||||
| BVAS | 0 | – | 0 | – | 0 | – |
| Time after diagnosis (months) | 168 (102–216) | – | 149 (82–201) | – | – | |
| Patients with relapse, n (%) | 5 (62.5%) | – | 12 (52.2%) | – | 6 (60%) | – |
| Number of relapses, n | 1 (0–3) | – | 1 (0–2) | – | 2 (0–3) | – |
| Laboratory findings | ||||||
| PR3-ANCA titer | 40 (0–80) | – | 40 (0–80) | – | 80 (0–160) | – |
| Leucocytes (× 109/l) | 6.0 (4.8–7.0) | – | 6.0 (5.3–6.9) | – | 6.3 (5.1–7.4) | – |
| CRP (mg/l) | 3 (1–6) | – | 3 (1–4) | – | 3 (2–6) | – |
| Current immunosuppressive treatment | 1 | 0 | 3 | 0 | 0 | 0 |
| Cyclophosphamide | 0 | 0 | ||||
| Azathioprine | 1 | 1 | ||||
| Prednisolone | 0 | 2 | ||||